Viva Biotech Revenues Surge on Move Into Contract Drug Manufacturing
Two key acquisitions last fall helped fuel fivefold rise in first-half revenue, as company swung back into profitability Key Takeaways: Viva Biotech’s fivefold jump in first-half revenues and move back…
RELATED ARTICLES
-
Cash-strapped Viva Biotech sells stake and plans spinoff
1873.HK
- FAST NEWS: Viva Biotech completes Langhua Pharma buyout
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK
-
Potential U.S. targeting casts shadow over WuXi AppTec family
2359.HK 603259.SHG
-
Akeso marks profit milestone with swift rights issue
9926.HK
-
BeiGene still bleeding red ink despite blockbuster drug
BGNE.US 6160.HK 688235.SHG
-
WuXi Biologics hatches new baby with ADC drug unit IPO
2269.HK
Discover hidden China stock gems in our weekly newsletter